Matthew Weston

Stock Analyst at UBS

(n/a)

# 3,841

Out of 4,804 analysts

3

Total ratings

n/a

Success rate

-12.46%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General

Stocks Rated by Matthew Weston

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	NVS Novartis AG	Downgrades: Neutral	n/a	$103.85	-	1	Feb 13, 2025
	AZN AstraZeneca	Upgrades: Buy	n/a	$66.76	-	2	Feb 13, 2025

Novartis AG

Feb 13, 2025

Downgrades: Neutral

Price Target: n/a

Current: $103.85

Upside: -

AstraZeneca

Feb 13, 2025

Upgrades: Buy

Price Target: n/a

Current: $66.76

Upside: -